100s of titles, one news app for just $10 a month.
Dive Deeper:
Immatics Initiates Phase 1 Clinical Trial of IMA401 in Advanced Solid Tumors
Immatics N.V. (NASDAQ: IMTX) announced the initiation of a Phase 1 clinical trial of its drug candidate IMA401 for patients…
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours:
Lantheus Holdings Doses First Patient in Phase 2 Clinical Trial of NM-01 for NSCLC
Lantheus Holdings, Inc. (NASDAQ: LNTH) dosed first patient in a Phase 2 trial evaluating NM-01, its proprietary technetium 99m SPECT…
One subscription that gives you access to news from hundreds of sites
COCP: Cocrystal Pharma Releases 2022 1st Quarter Results and Provides an Update on the Current Pipeline Programs
By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT
Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma
Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical…
Get all your news in one place
Latest Technology news:
Jony Ive had one wacky idea for Apple's mixed reality headset
A new report details Apple's internal conflicts over its long-rumored mixed reality headset and the odd features it might ship…
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
Genesis GV60 To Come With 3 Years Of Free Charging On The Electrify America Network
We examine the announcement that Electrify America and Genesis have partnered to offer three years of unlimited charging for Genesis…
Watch Ford's F-150 Lightning Tow A Trailer: How Far Can It Go?
Now that the Ford F-150 Lightning is shipping, we'll get to learn so much more about it from owners and…
AWD-Only 2023 Genesis GV60 Is On Sale In The US, Starts At $58,890
The GV60 is offered in two packages in the United States, GV60 Advanced and GV60 Performance; both feature dual-motor AWD…
Why the Internet Hates Amber Heard
Notes on the paranoid style in online fandom
From analysis to good news, read the world’s best news in one place
'Eiyuden Chronicle: Hundred Heroes' gameplay, trailer, platforms, and story
Rabbit & Bear's highly anticipated Suikoden spiritual successor, 'Eiyuden Chronicle: Hundred Heroes', is coming in 2023. Here's what we know…
Harry Styles is kicking off Apple's new series of livestreamed concerts
Apple Music Live will broadcast shows from "the biggest stars in music."

NGM Bio Initiates NGM438 Phase 1/1b trial for advanced solid tumors

By Ragothaman Srinivasan

NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM) initiated a Phase 1/1b clinical study of its drug candidate NGM438 for the treatment of patients with advanced solid tumors.

This clinical study initiation process brings all three of NGM Bio's wholly-owned myeloid reprogramming product candidates NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, NGM831, an ILT3 antagonist antibody, and NGM438 now into the clinic.

The dose-expansion trial will evaluate the potential of NGM438, as a monotherapy in combination with KEYTRUDA.

Hsiao D. Lieu, M.D., Chief Medical Officer, said, ”We’re thrilled to now have three myeloid checkpoint inhibition programs in the clinic. NGM707, NGM831 and NGM438 are directed at distinct myeloid checkpoints, each of which is suspected of playing a central role in impeding anti-tumor immunity”.

The company now anticipates initial interim top-line data readout from the Phase 1a portion of ongoing NGM707 Phase 1/2 trial in the second half of the year.

NGM Bio recently presented late-breaking preclinical data of NGM438 at the 2022 AACR Annual Meeting.

NGM Biopharmaceuticals closed Wednesdays trading down 9 percent at $10.58

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
Immatics Initiates Phase 1 Clinical Trial of IMA401 in Advanced Solid Tumors
Immatics N.V. (NASDAQ: IMTX) announced the initiation of a Phase 1 clinical trial of its drug candidate IMA401 for patients…
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours:
Lantheus Holdings Doses First Patient in Phase 2 Clinical Trial of NM-01 for NSCLC
Lantheus Holdings, Inc. (NASDAQ: LNTH) dosed first patient in a Phase 2 trial evaluating NM-01, its proprietary technetium 99m SPECT…
One subscription that gives you access to news from hundreds of sites
COCP: Cocrystal Pharma Releases 2022 1st Quarter Results and Provides an Update on the Current Pipeline Programs
By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT
Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma
Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical…
Get all your news in one place